Literature DB >> 15183251

Benefits of a rapid HIV test for evaluation of the source patient after occupational exposure of healthcare workers.

V Puro1, D Francisci, L Sighinolfi, R Civljak, B Belfiori, P Deparis, R Roda, R Modestino, F Ghinelli, G Ippolito.   

Abstract

Rapid human immunodeficiency virus (HIV) testing for the management of occupational exposure of healthcare workers significantly decreased the number of anti-retroviral post-exposure prophylaxis regimens started whilst awaiting HIV test results. The study confirmed an equivalent performance of the rapid test in comparison with HIV enzyme immunoassay, and suggests it is cost-effective. In addition, two other potential benefits emerged: reducing the number of source patients who remain untested and increasing the number of occupational exposures reported. Copyright 2004 The Hospital Infection Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183251     DOI: 10.1016/j.jhin.2004.03.004

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  3 in total

1.  HIV rapid screening tests and self-tests: Be aware of differences in performance and cautious of vendors.

Authors:  Thomas Mourez; Véronique Lemée; Valérie Delbos; Constance Delaugerre; Elodie Alessandri-Gradt; Manuel Etienne; François Simon; Marie-Laure Chaix; Jean-Christophe Plantier
Journal:  EBioMedicine       Date:  2018-10-24       Impact factor: 8.143

2.  Evaluation of the Performance of Health Extension Workers in HIV-1/2 Screening Tests: A Comparative Cross-Sectional Study, Addis Ababa, Ethiopia.

Authors:  Mulatu Gashaw; Samuel Kindie; Minale Fekadie; Kassu Desta; Dawit Wolday
Journal:  AIDS Res Treat       Date:  2020-11-19

3.  High risk for occupational exposure to HIV and utilization of post-exposure prophylaxis in a teaching hospital in Pune, India.

Authors:  Amita Gupta; Shuchi Anand; Jayagowri Sastry; Anandini Krisagar; Anita Basavaraj; Shreepad M Bhat; Nikhil Gupte; Robert C Bollinger; Arjun L Kakrani
Journal:  BMC Infect Dis       Date:  2008-10-21       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.